Abstract Cowden syndrome (CS) is a rare autosomal dominant disorder characterized by multiple hamartomas in various tissues and cancers (breast, thyroid, and endometrium). We report CS of the esophagus and gastrointestinal tract that was incidentally detected by positron emission tomography/ computed tomography (PET/CT) at postoperative surveillance in an endometrial cancer patient. PET/CT showed mildly increased FDG uptake along the entire esophagus and stomach. Upper GI endoscopy and histologic examination revealed glycogenic acanthosis of the esophagus and several hundred gastric polyps. In our case, increased FDG uptake of the esophageal wall contributed to the diagnosis of CS.
Introduction
Cowden syndrome (CS) is a rare autosomal dominant disorder characterized by multiple hamartomas in various tissues (skin, colon, thyroid, etc.) and cancers (breast, thyroid, and endometrium) [1] . The prevalence of CS is between 1 in 200,000 and 1 in 250,000. This syndrome is associated with mutations in the phosphatase and tensin homolog (PTEN) gene, a tumor suppressor gene [2] .
Here we report CS of the esophagus and gastrointestinal tract that was incidentally detected by postoperative positron emission tomography/computed tomography (PET/CT) in an endometrial cancer patient.
Case Report
A 60-year-old female with uterine endometrial cancer who underwent total hysterectomy with bilateral salpingooophorectomy 7 months ago visited our hospital for tumor surveillance. Additionally, uterine fibroid and endometrial polyps were found in the hysterectomy specimens. The patient's history included a thyroid lobectomy and total mastectomy 13 and 4 years ago, respectively, due to follicular aden o m a s a n d b r e a s t c a n c e r. S h e u n d e r w e n t F -1 8 fluorodeoxyglucose (FDG) PET/CT for a systemic evaluation of endometrial cancer. PET/CT showed mildly increased FDG uptake along the entire esophagus and stomach, but definite abnormality was not detected in other organs including the large colon (Fig. 1) .
On presentation, she complained of no symptom other than dyspepsia. Laboratory results were normal. Under the impression of gastritis and esophagitis, upper GI endoscopy was performed to further evaluate the lesions. It revealed diffuse whitish papules of the entire esophagus (Fig. 2a) , several hundred gastric polyps on the entire stomach (Fig. 2b) , several polyps on the duodenal bulb, and a focal erosion of the gastric antrum. Histologic examination showed glycogenic acanthosis of the esophagus (Fig. 3) , chronic duodenitis, and chronic active gastritis with focal lymphoid hyperplasia.
Based on the clinical and endoscopic features, she was diagnosed with Cowden syndrome in accordance with the criteria of the International Cowden Consortium. Colonoscopy was performed to examine the large bowel. It revealed multiple polyps scattered throughout the entire colon and terminal ileum. Histology of these colonic polyps showed a variety of cell types, including tubular adenomas, xanthoma, and hyperplastic polyps. Follow-up PET/CT, upper GI endoscopy, and colonoscopy were performed to check the lesions every year. On follow-up PET/CT, mildly increased FDG uptake along the entire esophagus and stomach was not changed, and there were no new lesions during this 3-year follow-up. At serial follow-up upper GI endoscopy and colonoscopy, there were no significant interval changes in polypoid lesions, and no erosion was detected during 3 years.
Discussion
Cowden syndrome (CS), or multiple hamartoma syndrome, was first described in 1963 by Lloyd and Denis in a case report on a patient named Rachel Cowden [3] . It is regarded as part of PTEN hamartoma tumor syndrome (PHTS), which includes CS, Bannayan-Riley-Ruvalcaba syndrome, adult Lhermitte-Duclos disease, and autism spectrum disorders associated with macrocephaly [4] . PTEN mutation frequency in individuals meeting the consortium diagnostic criteria has been recently reported to be about 30-35 %. CS is only associated with cancer predisposition in PHTS disorder. Approximately 30 % of CS patients are reportedly to be associated with specific cancer types, including breast cancer, thyroid cancer (follicular), endometrial cancer, renal cell carcinoma, and colon cancer [4, 5] .
CS is now well known as a highly variable multiorgan disease with cancer susceptibility as well as benign hamartomatous overgrowth. These hamartomas of CS patients can occur in any of three embryonic germ cell layers, and its origin may be ectodermal, mesodermal, or endodermal [2] . These lesions include trichilemmomas in 80-100 % of CS cases, breast fibroadenomas in 70-76 % of affected women, thyroid abnormalities such as adenomas and multinodular goiters in 40-60 % of CS cases, and gastrointestinal polyps in 35-65 % [4, 6] .
Diagnosis of CS is mainly based on clinical criteria. The diagnostic criteria for CS were first proposed by Salem and Steck in 1983. They were subsequently revised and modified by the International Cowden Consortium in 2000 [7] .
The pathognomonic manifestations of CS are mucocutaneous lesions such as trichilemmomas, palmoplantar keratosis, and oral mucosal papillomatosis. Its diagnosis was originally made based on characteristic cutaneous lesions and familial history [8] . Esophageal glycogenic acanthosis or GI hamartomas are considered minor criteria. However, in our case, FDG PET findings of the esophagus and stomach led to a further evaluation such as endoscopy, which showed esophageal glycogenic acanthosis as an endoscopic clue suggesting CS.
The characteristic finding of the esophagus in CS patients is diffuse glycogenic acanthosis. This has been found in 80 % of those undergoing evaluation. This lesion combined with colonic polyposis should be considered as pathognomonic for CS [4] .
To the best of our knowledge, there are very few reports on F-18 FDG PET/CT of CS. In 2012, Makis et al. reported a case of FDG-avid gastric cancer on the background of extensive benign gastric polyposis in a CS patient that showed no increase in FDG uptake in diffuse esophageal glycogenic acanthosis on PET/CT [9] . Kamel et al. reported one patient with glycogenic acanthosis of the esophagus incidentally detected on PET/CT that showed focally increased moderate FDG uptake in the esophagus [10] .
Increased FDG uptake on PET/CT is frequently noted in various benign lesions such as inflammation. The mechanism of FDG uptake in esophageal glycogenic acanthosis is a b c unclear. It might be related to the proliferative activity in this lesion [10] . The main differential diagnosis for hypermetabolic lesions of the esophagus are reflux esophagitis when interpreting PET/CT or PET studies. Other potential causes of abnormal PET findings may include Barrett's esophagus, eosinophilic esophagitis, and esophageal cancer [10] [11] [12] .
Our case indicates that esophageal glycogenic acanthosis should be included as a differential diagnosis of abnormal FDG uptake in the esophageal wall.
In conclusion, we report a rare case of esophageal glycogenic acanthosis showing diffuse increased FDG uptake on PET/CT imaging. In this case, increased FDG uptake of the esophageal wall contributed to the diagnosis of CS.
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